Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer
“Just under 100 non-small cell lung cancer patients in England will be eligible for the drug”
FDA Presses Clinical Hold Button For BioNTech’s Partner Late-Stage Trial Of Investigational Lung Cancer Treatment
“BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, randomized study evaluates BNT316/ONC-392 (gotistobart) as a monotherapy in patients with metastatic non-small cell lung cancer (NSCLC) who have previously progressed after PD-(L)1-inhibitor treatment.”
Complete Consolidative Radiotherapy May Have Survival Benefits in ES-SCLC
“Compared with incomplete consolidative radiotherapy, complete consolidative radiotherapy generally improved progression-free survival (PFS) and overall survival (OS) among patients with extensive-stage small cell lung cancer (ES-SCLC), according to James Ninia, MD.”
How Oral Azole Use Affects Immune Checkpoint Inhibitor Therapy for NSCLC
“Multivariable analysis indicated clotrimazole was the only individual azole identified to show an association with improved OS. Multivariable analysis also showed improved OS with using more than 1 azole and worse OS with miconazole.”
Estimating Costs Associated with Adverse Events in Patients with Advanced Lung Cancer
“Conclusion: Costs associated with AEs in advanced lung cancer patients treated with first-line therapies were substantial. These estimates could be adopted for future cost-effectiveness analyses of new lung cancer treatments.”
Understanding how deadly lung cancers control the local immune system
“Northwestern Medicine scientists have discovered how a protein in a deadly type of lung cancer can control how the immune system responds to the tumor, according to a study published in the Proceedings of the National Academy of Sciences.”
Complete Response to Immunotherapy in Stage IV Lung Cancer
“A case report highlights a 51-year-old man with stage IV non-small cell lung cancer and brain metastasis who received whole brain radiotherapy followed by immune checkpoint inhibitor treatment. The patient achieved complete response, with overall survival at 87 months and progression-free survival at 73 months, maintaining quality of life.”
New tool predicts risk of lung cancer’s spread to brain
“In a new study published in Nature Medicine UHN researchers have identified specific DNA changes that can predict a patient’s risk of cancer spreading to the brain, offering new approaches to managing patients and improving health outcomes.”
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
“The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on the skin to deliver alternating electrical fields, termed Tumor Treating Fields (TTFs), thereby disrupting malignant cell division while leaving healthy cells largely unaffected.”
First-line maintenance regimen improves OS, PFS in extensive-stage small cell lung cancer
“The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer. Lurbinectedin (Zepzelca; Jazz Pharmaceuticals, PharmaMar) is an RNA polymerase II inhibitor. Atezolizumab (Tecentriq, Genentech) is an anti-PD-L1 antibody.”
